Arcturus Therapeutics Holdings Inc.
ARCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768224
No open-market purchases or sales by Arcturus Therapeutics Holdings Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q3 2026, worth $345.6M in total; ARK Invest is the only superinvestor holding it.
Key figures
- Market capClose on Nov 20, 2026
- $214.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +18 vs. previous quarter
- 154
- 13F valueReported value at the end of Q3 2026
- $345.6M
- Superinvestors holdingAt the end of Q3 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $82.0M
- −46.1% year over year
- Net income, FY2025
- -$65.8M
- No comparable prior period
- Free cash flow, FY2025
- -$74.5M
- No comparable prior period
- Revenue, Q3 FY2026
- $18.3M
- +6.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $65.8M (80.2% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.41M
- Shares sold short
- Change
- −50.5K
- −0.9% vs. previous
- Days to cover
- 7.37
- At average daily volume
Superinvestors holding ARCT, Q3 2026
Go to the superinvestors tab1 superinvestor reports holding Arcturus Therapeutics Holdings Inc. on Form 13F. Percentages are the stock's share of each portfolio.
ARK Invest
Cathie Wood
0.2%
Arcturus Therapeutics Holdings Inc.'s share of the portfolio
- Shares
- 2,994,550
- Value
- $41.0M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Arcturus Therapeutics Holdings Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2025 (view filing) | Aug 15 | 5 days | Sassine AndyChief Financial Officer | PPurchase | +1.24K | $16.56 | +$20.5K | +0.6%221.8K after | Amended |
| Oct 16, 2024 (view filing) | Oct 15 | 1 day | Chivukula PadChief Scientific Officer & COO | SSale | −12.0K | $20.76 | −$249.1K | −2.7%435.3K after | 10b5-1 |
| Jun 14, 2024 (view filing) | Jun 12 | 2 days | Sassine AndyChief Financial Officer | SSale | −50.0K | $32.03 | −$1.60M | −18.5%220.5K after | |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −114 | $45.00 | −$5.13K | 0.0%447.3K after | 10b5-1 |
| Jun 4, 2024 (view filing) | Jun 3 | 1 day | Chivukula PadChief Scientific Officer & COO | SSale | −26.0K | $40.01 | −$1.04M | −5.5%447.4K after | 10b5-1 |
| Mar 27, 2024 (view filing) | Mar 25 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −17.4K | $35.02 | −$610.6K | −3.6%473.4K after | 10b5-1 |
| Mar 21, 2024 (view filing) | Mar 19 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −8.56K | $35.01 | −$299.9K | −1.7%490.9K after | 10b5-1 |
| Nov 3, 2023 (view filing) | Nov 1 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −5.00K | $18.72 | −$93.6K | −1.0%499.4K after | 10b5-1 |
| Oct 4, 2023 (view filing) | Oct 2 | 2 days | Chivukula PadChief Scientific Officer & COO | SSale | −5.00K | $25.61 | −$128.1K | −1.0%504.4K after | 10b5-1 |
| Sep 5, 2023 (view filing) | Sep 1 | 4 days | Chivukula PadChief Scientific Officer & COO | SSale | −5.00K | $31.45 | −$157.3K | −1.0%509.4K after | 10b5-1 |
Top 10 13F holders, Q3 2026
See all 154 holdersThe largest institutional positions in Arcturus Therapeutics Holdings Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 2,994,550 | $41.0M | 0.24% | +92,915+3.2% | Added |
| BlackRock, Inc. | 2,694,816 | $36.9M | 0.00% | +80,804+3.1% | Added |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,689,107 | $23.1M | 0.01% | −274,016−14.0% | Reduced |
| Nikko Asset Management Americas, Inc. | 1,689,107 | $23.1M | 0.29% | −271,351−13.8% | Reduced |
| Federated Hermes, Inc. | 1,678,069 | $23.0M | 0.03% | −1,625,571−49.2% | Reduced |
| Two Sigma Investments, LP | 1,231,847 | $16.9M | 0.01% | +140,710+12.9% | Added |
| Vanguard Capital Management LLC | 1,107,056 | $15.2M | 0.00% | −7,900−0.7% | Reduced |
| D. E. Shaw & Co., Inc. | 976,120 | $13.4M | 0.01% | +583,762+148.8% | Added |
| Vanguard Portfolio Management LLC | 861,240 | $11.8M | 0.00% | −90,335−9.5% | Reduced |
| Jacobs Levy Equity Management, Inc | 703,060 | $9.62M | 0.03% | +55,549+8.6% | Added |
Holders of 5% or more of ARCT
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Arcturus Therapeutics Holdings Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| ARK Investment Management LLCSuperinvestorARK Invest | 13G/A | 10.37%2.95M shares | +1.18 ppfrom 9.19% | Feb 16, 20218 filings | May 7, 2026 | SEC |
| Meiji Seika Pharma Co., Ltd. | 13G | 7.88%2.47M shares | New | Nov 18, 20261 filing | Nov 18, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.80%2.10M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
| Nikko Asset Management Americas, Inc. | 13G/A | 5.90%1.69M shares | −1.30 ppfrom 7.20% | Feb 14, 20227 filings | Nov 13, 2026 | SEC |
| Sumitomo Mitsui Trust Holdings, Inc. | 13G/A | 5.90%1.69M shares | −1.30 ppfrom 7.20% | Feb 4, 20227 filings | Oct 29, 2026 | SEC |